We found that the expression of the activation markers CD38, CD69, and HLA-DR decreased on TN and TCM subsets in DN-CML patients and further decreased in TKI-F patients. The gene discussed is CD69; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.